Major Shareholders Criticize Enzon Pharmaceuticals Management Team in Open Letter
Investors Specify Concerns and Propose Remedies to Enzon
CEO Jeffrey Buchalter and the Board of Directors
NEW YORK, Jan. 30 /PRNewswire/ -- On January 28, 2009, Knott Partners and affiliated funds, which own approximately 1.8 million shares of outstanding common stock of Enzon
Sanofi-Aventis Recognized for Workplace Efforts to Prevent Cancer
...ealth threat: American Cancer Society, American Legacy Foundation, AstraZeneca, C-Change, CIGNA, Dana-Farber Cancer Institute, Duke Medicine, Edelman, enzon
Pharmaceuticals, GHI, GlaxoSmithKline, Jenner & Block, Johnson & Johnson, The Lance Armstrong Foundation, MD Anderson Cancer Center, Millenniu...
Flashpoint Launches Flashlight Interactive, Names Kristen Goelz Head of New Division
...ice professional agency focused on defining a brand's flashpoints
by bringing unexpected solutions to ignite a brand's growth. Clients
include Cordis, enzon
Pharmaceuticals, Forest Laboratories, Genentech,
Indevus Pharmaceuticals, Inc., Integra, Novogyne Pharmaceuticals, and UCB.
Flashlight Interactive i...
Flashpoint Medica Named Agency of Year by Medical Advertising News
...lty brands. Flashpoint manages three megabrands,
serving as agency of record for clients that include Genentech, Johnson &
Johnson-Cordis, UCB Pharma, enzon
Pharmaceuticals and Indevus
Pharmaceuticals. The agency provides a full range of services, including
brand development, positioning, professional and ...
QED International Associates Announces Quarterly Rebalancing of HealthShares(TM) Indexes
...Laboratories Inc. (Nasdaq: DSCO ) Eisai Co. Ltd. (TSE: 4523.T) Encysive Pharmaceuticals Inc. (Nasdaq: ENCY ) Enzo Biochem Inc. (NYSE: ENZ ) enzon
PHARMACEUTICALS INC. (Nasdaq: ENZN ) Exelixis Inc. (Nasdaq: EXEL ) Flamel Technologies (Nasdaq: FLML ) Illumina Inc. (Nasdaq: ILMN ) Incyt...
Three Organizations Receive CEO Cancer Gold Standard(TM) Accreditation
...tation from the CEO Roundtable on Cancer.
They are: American Cancer Society (national headquarters), American Legacy
Foundation, AstraZeneca, Edelman, enzon
Jenner & Block, Johnson & Johnson, MD Anderson Cancer Center, Novartis, OSI
Pharmaceuticals, Quintiles Transnational...
Pharmacopeia Announces Senior Additions to Management Team
...eia, Mr. Liebler served most recently as
Senior Vice President, Strategic Planning at Questcor Pharmaceuticals and
held executive-level positions with enzon
Corporation, Amarin Pharmaceuticals, and Athena Neurosciences. Mr. Liebler
currently serves as Vice Chairman of the Board of Tru...
Enzon in Medical Technology
Expert Insights in Acute Lymphoblastic Leukemia: Current Challenges and Future Directions
...nt Challenges and Future Directions . This activity, which features an interactive, expert panel discussion, is supported by an educational grant from enzon
Pharmaceuticals and is certified for nurses and pharmacists.
Charles A. Schiffer, MD, Professor of Medicine at Wayne State University School of...
Another LNA-based RNA Inhibitor Enters Clinical Trials
...od and Drug Administration (FDA) recently
PharmaÂceutical's Investigational New Drug (IND) ... inhibitors being developed by
Santaris Pharma and enzon
Pharmaceuticals through a comprehensive partnershi...iety of cancers. Under the
terms of the agreement, enzon
will have exclusive rights to develop and
Enzon to Present Preclinical Data From PEG-SN38 and PEGylation
Technology Studies at AACR Meeting
...M, PT, Poster Section 25, Poster Board 9.)
Pharmaceuticals, Inc. is a biopharmaceutical compa...with cancer and other
life-threatening conditions. enzon
has a portfolio of four marketed
Santaris Pharma presents positive preclinical data on SPC2996 at
the American Association for Cancer Research
Pharma completed a Euro 40m second round of equity financing in May
2006. In July 2006, the Company entered into a global partnership
Pharmaceuticals of New Jersey to co-develop and
commercialise a series of Santaris RNA Antagonists for improving
the treatment of cancer.
Enzon in Biological Technology
Santaris Pharma Delivers Six LNA-Based RNA Inhibitors to Enzon Pharmaceuticals Ahead of Schedule
COPENHAGEN, April 27 /PRNewswire/ -- As a testimony to the strength of
Santaris Pharma's efficient Drug Discovery Engine, the Company announced
today the completion of the delivery of six cancer target drug candidates to
their collaboration partner Enzon
Pharmaceuticals. All six drug candidate...
Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
TORONTO, Aug. 27 /PRNewswire/ -- Drug Royalty LP 2 (DRC) announced
today the purchase of 25% of Enzon
Pharmaceuticals, Inc.'s (ENZN) worldwide
royalty interest in PEG-INTRON for $92.5M. DRC will also provide a $15M
milestone payment in 2012 should certain royalty recognition levels be met.
Santaris Pharma - Interim Report for the Period 1 January to 30 June 2009
Santaris Pharma's collaboration partner enzon
preliminary results of t...targeting
solid tumors at the AACR meeting in May. enzon
expects to report the results
of its phase I clini...mors with EZN2968 in the 2nd
half of 2009. Further enzon
has announced its intention of initiation of a
World Nanomedicine Market to Cross $160 Billion by 2015, According to New Report by Global Industry Analysts, Inc.
...clude Abraxis BioScience Inc., AMAG Pharmaceuticals Inc, Arrowhead Research Corporation, Crucell N.V., Flamel Technologies S.A., Elan Corporation Plc, enzon
Pharmaceuticals Inc., Life Technologies Corporation, Nanosphere Inc., Nektar Therapeutics, Novavax Inc., Oxonica Plc, Par Pharmaceutical Companies Inc...
LNA-Based HIF-1 Alpha Inhibitor Shows Early Signs of Clinical Benefit
...ted with poor prognosis and
resistance to therapy. enzon
is currently conducting two Phase I studies,
evalu... The collaboration between Santaris Pharma and enzon
started in 2006 and by 2008 Santar...arma had delivered eight LNA based
cancer drugs to enzon
Pharmaceuticals of which EZN-2968 was the first. T...
Mergent, Inc. Announces Quarterly Rebalancing of HealthShares(TM) Indexes
...ON CORP (NASDAQ: DNDN ) DENTSPLY INTERNATIONAL INC. (NASDAQ: XRAY ) DISCOVERY LABORATORIES INC. (NASDAQ: DSCO ) ENZO BIOCHEM INC. (NYSE: ENZ ) enzon
PHARMACEUTICALS INC. (NASDAQ: ENZN ) EXPRESS SCRIPTS INC. (NASDAQ: ESRX ) FLAMEL TECHNOLOGIES-ADR (NASDAQ: FLML ) GERON CORP (NASDAQ: GERN ) H...
QED International Associates Announces Quarterly Rebalancing of HealthShares(TM) Indexes (As Revised)
...ery Laboratories Inc. (Nasdaq: DSCO ) Eisai Co. Ltd. (TSE: 4523.T) Encysive Pharmaceuticals Inc. (Nasdaq: ENCY ) Enzo Biochem Inc. (NYSE: ENZ ) enzon
PHARMACEUTICALS INC. (Nasdaq: ENZN ) Exelixis Inc. (Nasdaq: EXEL ) Flamel Technologies (Nasdaq: FLML ) Illumina Inc. (Nasdaq: ILMN ) Incyte Co...
BioSpace New Jersey Career Fair Attracts Over 1,000 Bioscience Candidates
...es recruiting at the event interviewed
candidates from a deep talent pool throughout the day. Sean Fitzmorris,
Recruiting Manager at Bridgewater-based enzon
"Enzon has attended quite a few BioSpace Career Fairs and we will continue
to exhibit at these events due to the number of qu...
BioSpace, BioNJ and Pennsylvania Bio Welcome Over 800 Life Science Career Candidates to Biotech 2007 Career Fair
...rchasing agents, pharmaceutical marketing professionals, and
many others attended to interview with top life science firms. Companies
such as Covance, enzon
Pharmaceuticals, Human Genome Sciences, Roche
Molecular Systems, Solstice Neurosciences, Vertex Pharmaceuticals and
others were hiring for pharmaceuti...
Jeffrey H. Buchalter Joins MacroGenics Board of Directors as Chairman
its rich pipeline, platforms, and product development capabilities." Mr. Buchalter currently serves as President, CEO and Chairman of the
Board of enzon
Pharmaceuticals, Inc. (Nasdaq: ENZN ), a biopharmaceutical
company dedicated to the development and commercialization of therapeutics
for cancer and ...